Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCXP01
- Development stage
- Preclinical
- Lead developer
- Genovyn
- Modality
- Small Molecules
01
Overview
BCXP01 is a preclinical small molecule drug candidate being developed by Genovyn. It is designed as an LBCX inhibitor for the treatment of immuno-oncology indications, including cancer and autoimmune diseases. The program is currently in the early stages of preclinical discovery, with target identification in progress.
Beyond the preview
Go deeper on BCXP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCXP01.